

In the Claims

Pursuant to 37 C.F.R. §1.121(c)(1), please cancel claim 2 without disclaimer or prejudice to applicants' rights to pursue the subject matter of this claim in this or another application. Additionally, please amend claim 1 and add new claims 62-66 pursuant to 37 C.F.R. §1.121(c)(1) as set forth below. The additions to the claims are indicated by underlining added material in the Version with Markings to Show Changes Made attached hereto as **Exhibit 1**.

B' 1. (Amended) A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of Copolymer 1 (glatiramer acetate), and an amount of microcrystalline cellulose in excess of 50 % by weight of the composition.

B² 62. (New) The pharmaceutical composition of claim 3 in solid form.

63. (New) The pharmaceutical composition of claim 62, wherein the solid form is selected from the group consisting of a tablet, a hard gelatin capsule, a pellet and a particulate formulation.

64. (New) The process of claim 43, further comprising applying a film coating.

65. (New) The process of claim 43, further comprising applying an enteric coating.

66. (New) The process of claim 45, wherein the enteric coating is applied using a rotating pan system.